Science 37 taps NuvoAir to enable remote collection of lung health endpoints
NuvoAir has developed a digital respiratory care platform that features a suite of connected devices, including a CE marked and Food and Drug Administration cleared Bluetooth spirometer that enables patients to measure their lung health at home. The suite also includes a sensor that attaches to inhalers to track when and how patients take medications, an app that counts nightly coughs and more.
The platform, which also features an integrated patient app, clinician software and a wrap-around clinical service, has the potential to facilitate the remote collection of data for clinical trials. Rather than travel to a trial site to have their lung function assessed, patients could use the connected spirometer to capture data points such as the amount of air they can force from their lungs in one second.
NuvoAir’s potential to shift data collection from sites to the home aligns it with the focus of Science 37, the provider of an operating system designed to enable hybrid and decentralized clinical trials.
Science 37 has now secured the chance to incorporate NuvoAir’s remote spirometry capabilities into its clinical trials, enabling it to offer an expanded range of options to sponsors that want to capture data in respiratory studies remotely.
“In previous respiratory studies, we have used spirometry equipment and nurse training that replicates the equipment and training being used at brick-and-mortar sites. The partnership with NuvoAir affords us the opportunity to explore the use of additional connected respiratory devices that will provide more operational choices to our patients and pharma partners,” said a spokesperson for Science 37.
The NuvoAir technology will slot into a portfolio that helped Science 37 generate sales of $19.3m in the second quarter, up 54% compared to the same period in 2021. However, net bookings were down, a trend the firm attributed to “a strategic shift in sales strategy to focus on larger studies, which generally have a longer bookings conversion timeline,” and it made another loss as it invested in the business.
